Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis

Medical Science Monitor

Volumn 15, Issue 1, 2009, Pages

  Akira, Shigeo ^a   Mine, Katsuya ^a   Kuwabara, Yoshimitsu ^a   Takeshita, Toshiyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Adenomyosis; Bone mineral density; Estrogen therapeutic window; GnRH agonist; Low dose GnRHa therapy

Indexed keywords

BUSERELIN ACETATE; CA 125 ANTIGEN; ESTRADIOL; GONADORELIN AGONIST;

ADENOMYOSIS; ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; HOT FLUSH; HUMAN; LOW DRUG DOSE; LUMBAR VERTEBRA; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; RETROSPECTIVE STUDY; TREATMENT DURATION; VISUAL ANALOG SCALE; WITHDRAWAL BLEEDING;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; BONE DENSITY; BUSERELIN; CA-125 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIOSIS; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUMBAR VERTEBRAE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58649100231     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benson RC, Sneeden VD: Adenomyosis: A reappraisal of symptomatology. Am J Obstet Gynecol, 1958; 76: 1044-57
2. Vercellini P, Parazzini F, Oldani S et al: Adenomyosis at hysterectomy: a study on frequency, distribution and patient characteristics. Hum Reprod, 1995; 10: 1160-62
3. Nishida M: Relationship between the onset of dysmenorrhea and histologic findings in adenomyosis. Am J Obstet Gynecol, 1991; 165: 229-31
4. Togashi K, Ozasa H, Konishi I et al: Enlarged uterus: differentiation between adenomyosis and leiomyoma with MR imaging. Radiology, 1989; 171: 531-34
5. Reinhold C, Tafazoli F, Wang L: Imaging features of adenomyosis. Hum Reprod Update, 1998; 4: 337-49
6. Wood C: Surgical and medical treatment of adenomyosis. Hum Reprod Update, 1998; 4: 323-36
7. Comite F: GnRH analogs and safety. Obstet Gynecol Surv, 1989; 44: 319-25
8. Grow DR: Treatment of adenomyosis with long-term GnRH-analogues: a case report. Obstet Gynecol, 1991; 78: 538-39
9. Nelson JR, Corson SL: Long term management of adenomyosis with a gonadotropin releasing hormone agonist: a case report. Fertil Steril, 1993; 59: 441-43
10. Barbieri RL: Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol, 1992; 166: 740-45
11. Leather AT, Studd JW, Watson NR, Holland EF: The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet Gynecol, 1993; 81: 104-7
12. Hornstein MD, Surrey ES, Weisberg GW, Casino LA: Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol, 1998; 91: 16-24
13. Monroe SE, Blumenfeld Z, Andreyko JL et al: Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab, 1990; 63: 1334-41
14. Jacobson H, Harris SR, Bullingham RE: Low dose intranasal nafarelin for the treatment of endometriosis. Acta Obstet Gynecol Scand, 1994; 73: 144-50
15. Uemura T, Shirasu K, Katagiri N et al: Low-dose GnRH agonist therapy for the management of endometriosis. J Obstet Gynecol Res, 1999; 25: 295-301
16. Tahara M, Matsuoka T, Yokoi T et al: Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back") therapy. Fertil Steril, 2000; 73: 799-804
17. Uemura T, Mohri J, Osada H et al: Effect of gonadotropin-releasing hormone agonist on the bone mineral content of patients with endometriosis. Fertil Steril, 1994; 62: 246-50
18. Morrison NA, Oi JC, Tokita A et al: Prediction of density from vitamin D receptor alleles. Nature, 1994; 367: 284-87
19. Surrey ES: Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fertil Steril, 1995; 64: 673-85
20. Vassilopoulou-Sellin R: Breast cancer and hormonal replacement therapy. Ann NY Acad Sci, 2003; 997: 341-50
21. World Health Organization (WHO): Medical eligibility criteria for contraceptive use. Geneva, Switzerland: WHO 2004